Nurix Therapeutics Announces Proposed Public Offering

Rhea-AI Summary

Nurix Therapeutics, Inc. (Nasdaq: NRIX) announces a $125 million public offering of common stock and pre-funded warrants to fund clinical development and research activities.

Financial Analyst

The initiation of a public offering by Nurix Therapeutics, Inc. represents a significant financial event that warrants attention from a capital markets perspective. The decision to raise $125 million through the sale of common stock and pre-funded warrants indicates an aggressive capital-raising strategy, likely aimed at accelerating the clinical development of the company's drug candidates. The underwriters' 30-day option to purchase additional shares suggests confidence in investor demand, potentially increasing the total capital raised.

From a financial standpoint, the influx of funds could strengthen Nurix's balance sheet, providing the necessary liquidity for sustained R&D efforts. However, the dilutive effect of the new equity on existing shareholders must be considered. The market's reaction to such offerings is typically mixed, with the potential for short-term stock price volatility. Investors should monitor the final terms of the offering, as they will impact Nurix's market capitalization and shareholder equity.

Market Research Analyst

Biopharmaceutical companies like Nurix Therapeutics are heavily reliant on capital for research and development, making this offering a strategic move to secure funding without incurring debt. By analyzing the competitive landscape, it is evident that access to capital is a key differentiator for companies in the race to bring new drugs to market.

Investors should note that the success of such offerings often hinges on the company's pipeline potential and market sentiment towards the biopharmaceutical sector. The involvement of established financial institutions as book-runners and lead managers could be interpreted as a positive signal, potentially attracting institutional investors and bolstering confidence in the offering.

Biotech Industry Analyst

The biotech industry is characterized by long development cycles and high regulatory hurdles. Nurix's focus on targeted protein modulation drugs for cancer and inflammatory diseases places it in a high-stakes, high-reward sector. The proceeds from the offering earmarked for clinical development and R&D activities indicate an aggressive push to advance the company's pipeline.

Investors should assess the therapeutic areas addressed by Nurix's candidates, as well as the company's track record in advancing drugs through clinical trials. The outcome of these developments will have long-term implications for the company's growth and market positioning. It is important to weigh the potential of Nurix's scientific approach against the inherent risks of clinical trial failures or regulatory setbacks.

SAN FRANCISCO, April 11, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that it has commenced an underwritten public offering of $125 million of its common stock and, in lieu of common stock, in the case of certain investors, pre-funded warrants to purchase shares of its common stock. In addition, Nurix intends to grant the underwriters a 30-day option to purchase additional shares of its common stock at the public offering price less underwriting discounts and commissions. All of the securities will be offered and sold by Nurix. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

J.P. Morgan Securities LLC, Piper Sandler & Co. and Stifel, Nicolaus & Company, Incorporated are acting as joint book-running managers for the proposed offering. Needham & Company, LLC and RBC Capital Markets, LLC are acting as lead managers for the proposed offering.

Nurix currently intends to use any net proceeds from this offering primarily to fund clinical development of its drug candidates, to fund research and development activities to expand its pipeline and for working capital and general corporate purposes.

The public offering will be made pursuant to a shelf registration statement on Form S-3 (File No. 333-258448) that was previously filed by Nurix with the Securities and Exchange Commission (“SEC”) on August 4, 2021, which was subsequently amended on February 9, 2023, by Post-Effective Amendment No. 1 and Post-Effective Amendment No. 2 and declared effective on April 6, 2023. A preliminary prospectus supplement relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus and accompanying prospectus relating to the offering will be available, when filed, on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus and the accompanying prospectus relating to the offering may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204, or via email at prospectus-eq_fi@jpmchase.com; Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800) 747-3924, or via email at prospectus@psc.com; or Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720, or via email at syndprospectus@stifel.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Nurix, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Nurix Therapeutics, Inc.

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. Leveraging extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform, to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin-proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned, clinical stage pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates activation of multiple immune cell types including T cell and NK cells. Nurix is headquartered in San Francisco, California.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein that do not describe historical facts, including, but not limited to, statements regarding Nurix’s intention to conduct an offering and sale of its securities, the grant of the option to purchase additional shares, the ability to complete the proposed offering and the expected use of proceeds, are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Such risks and uncertainties include, among others, the risks identified in Nurix’s filings with the SEC, the prospectus related to the offering, and subsequent filings with the SEC. Any of these risks and uncertainties could materially and adversely affect Nurix’s results of operations, which would, in turn, have a significant and adverse impact on Nurix’s stock price. Nurix cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Nurix undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made or to reflect the occurrence of unanticipated events.

Investor Contacts:
Jason Kantor, Ph.D
Nurix Therapeutics
ir@nurixtx.com

Elizabeth Wolffe, Ph.D
Wheelhouse Life Science Advisors
lwolffe@wheelhouselsa.com

Media Contact:
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com

FAQ

What did Nurix Therapeutics announce?

Nurix Therapeutics announced a $125 million public offering of its common stock and pre-funded warrants.

What is the ticker symbol for Nurix Therapeutics?

The ticker symbol for Nurix Therapeutics is NRIX.

How does Nurix plan to use the net proceeds from the offering?

Nurix intends to use the net proceeds primarily to fund clinical development of its drug candidates, research and development activities, pipeline expansion, and for working capital and general corporate purposes.

Who are the joint book-running managers for the proposed offering?

J.P. Morgan Securities , Piper Sandler & Co., and Stifel, Nicolaus & Company, Incorporated are acting as joint book-running managers for the proposed offering.

Where can one find the preliminary prospectus supplement for the offering?

The preliminary prospectus supplement will be filed with the SEC and will be available on the SEC's website at www.sec.gov.